首页
400-620-6333
IFN-γ
| 别名 | interferon gamma, immune interferon, Actimmune® |
|---|---|
| Compound Class | Peptide |
| 变动原因 | IFN-γ is a type II interferon. It is biologically active as a homodimer. |
| Species |
Human |
| Related Product | IFN-γ |
Summary
| 基因/前体 |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 是否批准为药物？ | (FDA (1999)) | ||||||||||
| IUPAC Name | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
| 别名 | interferon gamma, immune interferon, Actimmune® |
数据库链接
| UniProtKB | P01579 |
|---|---|
| Wikipedia | Interferon_gamma |
| RCSB PDB Structure | 1FG9 |
| Ensembl Gene | ENSG00000111537 |
| DrugBank Target | P01579 |
| IMGT/mAb-DB | 638 |
| PEP | interferon-gamma (ifn-γ) |
生物活性
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
|---|---|
| 关联靶标 | Interferon-γ receptor |
临床资料
| Summary of Clinical Use | Recombinant IFNγ is approved to reduce the frequency of serious infection in chronic granulomatous disease (CGD) and severe malignant osteopetrosis . |
|---|---|
| 作用机制与药效学效应 |
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants |
结构
| Peptide Sequence | QDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRG |
|---|---|
| Post Translation Modifications | Residue one is pyrrrolidine carboxylic acid; N linked glycosylation of asparagine residue at position 25; N-linked glycosylation of asparagine at position 97 in the dimeric form |
危险品化学品经营许可证（带存储）